Robert C. Goeltz II, Chief Financial Officer at Arcus Biosciences, Inc. (RCUS), sold 25,324 shares at $22.16 ($557K) on 2025-12-17, disclosed to the SEC on 2025-12-18.
Scheduled sale ($557k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.88 | 6,702 | $147K | 26.3% |
| 2 | $21.88 | 6,702 | $147K | 26.3% |
| 3 | $22.16 | 5,960 | $132K | 23.7% |
| 4 | $22.16 | 5,960 | $132K | 23.7% |
| Total | $22.01 avg | 25,324 | $557K | 100% |
| Filing → |
| RCUS | SELL | 2025-11-26 | $125K | — | Filing → |
| RCUS | SELL | 2025-10-29 | $100K | — | Filing → |
| RCUS | SELL | 2025-01-03 | $54K | — | Filing → |